Davy James, Managing Editor

Duration of sleep and snoring may play a role in survival outcomes.

Top stories of the week on Specialty Pharmacy Times from June 8-12.

Agency notes that expedited approvals do not compromise quality standards.

Study finds greater unmet needs for basic services compared with male patients.

Early palliative care reduces costs more than traditional treatment standards.

Men with AR-V7 variant more likely to be resistant to hormone drugs.

Researchers find cooperation among viral variants that help hepatitis C to survive.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses methods to address the growing cost of specialty medications.

Glioblastoma treatment with surgical resection may benefit patients with worst prognoses.

Undertreated side effects in treatment of some colon and stomach cancers need to be addressed.

Costs grow for people with oral cavity and pharyngeal cancers based on demographics, co-existing illnesses, and treatment selection.

Biological mechanisms of breast milk may have preventative effect.

Nivolumab extends life by 3.2 months compared with chemotherapy.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the National Association for Specialty Pharmacy and their efforts to enhance the specialty space.

Nivolumab has increased the survival rate in patients with low grade adverse events.

A look back at the top stories of the week on Specialty Pharmacy Times.

Extracts show strong activity in treatment of cervical cancer cells.

Drug found to improve physical function.

Combination therapy with AKT inhibitors shows promise.

Marketplace users less likely to use most medication classes except for hepatitis C and HIV.

David Lassen, chief clinical officer at Prime Therapeutics, discusses methods to overcome the impact of increasingly high copays on patient adherence.

Chemotherapy combination extends progression-free survival over standard chemotherapy.

Research seeks to determine how cancer cells avoid chemotherapy.

High level of benefit found in Gazyva compared with bendamustine.

Melanoma incidence increased 250% in children, adolescents and young adults since 1973.

Gene mutations found in some patients provide hope for new and existing treatments.

Predictive model uses routine lab values and machine learning method.

Therapy disrupts signals that fuel inflammation.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group discusses how the relationship between manufacturers, providers, and specialty pharmacies can be improved.

A pair of large RNA classes associated with a protein that may play a role in cancer progression.